Successful downstaging of high rectal and recto-sigmoid cancer by neo-adjuvant chemo-radiotherapy

Brian O'Neill, Gina Brown, Andrew Wotherspoon, Sarah Burton, Andy Norman, Diana Tait, Brian O'Neill, Gina Brown, Andrew Wotherspoon, Sarah Burton, Andy Norman, Diana Tait

Abstract

Purpose: The benefit of neoadjuvant therapy for tumours above the peritoneal reflection is not clear. The purpose of this study is to demonstrate the feasibility and downstaging of treating locally advanced tumours from high rectum to distal sigmoid with preoperative chemoradiotherapy (CRT).

Methods and materials: Seventeen patients with high rectal, rectosigmoid or distal sigmoid tumours above the peritoneal reflection received neoadjuvant CRT, selected on MRI findings indicating T4 disease or threatened circumferential resection margin. All patients were administered neoadjuvant chemotherapy, with Oxaliplatin or Mitomycin C and a Fluoropyrimidine. The pelvis received long-course CT-planned conformal RT, 45 Gy in 25 fractions, with a boost of 5.4-9 Gy in 3-5 fractions. Thirteen patients were treated with concomitant oral or intravenous Fluoropyrimidine chemotherapy.

Results: Median follow-up was 37 months. Overall survival was 82.35% (95% Confidence Interval (CI) 54.7-93.9) and disease free survival 81.25% (95% CI 52.5-93.5). Only 1 patient suffered loco-regional relapse. Chemotherapy regimens were well tolerated, though some patients required dose reductions. Nine patients (52.9%) lowered pathologic disease AJCC stage, i.e. 'downstaged'. Six patients (35.3%) achieved complete pathological response. Clear margins were attained in all but 1 patient. Three patients were converted from cT4 to ypT3. No patient required a gap during CRT. One patient suffered a grade III acute toxicity, but no grade IV (RTOG). There were 3 grade III and 3 grade IV late toxicities (LENT-SOMA).

Conclusions: Locally advanced high rectal and recto-sigmoid tumours may be treated with pre-operative CRT with acceptable toxicity, impressive down-staging, and clear surgical margins.

Keywords: chemoradiotherapy; chemotherapy; downstaging; radiotherapy; total mesorectal excision.

Figures

Figure 1
Figure 1
Axial and Sagittal phase I planning CT showing planning target volume (thick line) and 95% isodose (thin line). Note a higher than standard superior border to cover primary disease with a 3 cm margin.
Figure 2
Figure 2
Axial and Sagittal phase II planning CT showing planning target volume (thick line) and 95% isodose (thin line). Note a 2 cm margin around the gross tumour volume (including nodal disease in the mesorectum), with anterior sacrum included.
Figure 3
Figure 3
Patient 1: Sagittal T2 weighted fast spin echo (TR3900 TE 120) MRI scans of a) pre-chemoradiotherapy, showing a large rectal tumour (open arrow) almost entirely above the peritoneal reflection (arrow), and b) marked tumour regression and downsizing 4 weeks post-chemoradiotherapy, with areas of low signal intensity indicating fibrosis (open arrow).
Figure 4
Figure 4
Patient 1: Coronal oblique imaging axial to Recto—Sigmoid, T2 weighted fast spin echo (TR4000 TE 120) MRI scans demonstrating: evidence of Recto-Sigmoid adenocarcinoma downstaging with neoadjuvant chemoradiotherapy. a) Annular tumour invading extensively into the mesorectum, with a threatened circumferential surgical margin (arrow) and tumour also appears to have perforated through the peritoneal reflection (open arrow). Preoperative chemoradiotherapy was administered. b) Scans 4 weeks following completion of therapy. There has been remarkable tumour regression, with low signal intensity indicating fibrosis (arrow) and margins no longer appear threatened. There is fibrosis (low signal intensity) at the peritoneal reflection. c) Surgical specimen confirms fibrosis (arrows). This was an R0 resection.
Figure 5
Figure 5
Patient 2: Sagittal T2 weighted fast spin echo (TR3900 TE 120) MRI scans of a) pre-chemoradiotherapy, showing a large rectal tumour (open arrow) arising entirely above the peritoneal reflection (arrowed) into the sigmoid colon, almost to the level of S1/2, and b) considerable tumour regression and downsizing 4 weeks post-chemoradiotherapy, with extensive low signal intensity indicating fibrosis (open arrow), consistent with a radiological complete response.
Figure 6
Figure 6
Patient 2: Oblique axial T2 weighted fast spin echo (TR4000 TE 120) MRI scans demonstrating evidence of Recto-Sigmoid adenocarcinoma downstaging with neoadjuvant chemoradiotherapy. a) Near circumferential tumour abuts (arrowed) the peritoneal surface and fibroid uterus. Preoperative chemoradiotherapy was delivered. b) Scans 4 weeks following completion of therapy. There has been very considerable tumour regression, with extensive low signal intensity indicating fibrosis (arrowed). Appearances are in keeping with a radiological complete response. c) Surgical specimen confirms fibrosis (arrowed) and was a pathological complete response.

References

    1. ICRU report 50: Prescribing, recording and reporting photon beam therapy. ICRU; Bethesda, MD: 1993.
    1. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980–7.
    1. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358:1291–304.
    1. AJCC Cancer Staging Handbook. Sixth edition. American Joint Committe on Cancer; 2002.
    1. Balch GC, Mithani SK, Shyr Y, et al. Prognostic significance of response to neoadjuvant chemoradiation therapy for rectal cancer. ASCO Annual Meeting, abstr. 2003;1047
    1. Burton S, Brown G, Daniels I, et al. MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid and upper rectum: Treatment with radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:445–51.
    1. Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Jama. 2000;284:1008–15.
    1. Chau I, Allen M, Cunningham D, et al. Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. Br J Cancer. 2003;88:1017–24.
    1. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668–74.
    1. Gerard JP, Bonnetain F, Conroy T, et al. Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3–4 rectal cancers: results of the FFCD 9203 randomized trial. Journal of Clinical Oncology. 2005;23:247s. suppl; abstr 3504.
    1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1:1479–82.
    1. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.
    1. Marr R, Birbeck K, Garvican J, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg. 2005;242:74–82.
    1. Martenson JAJR, Willett CG, Sargent DJ, et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol. 2004;22:3277–83.
    1. Mawdsley S, Glynne-Jones R, Grainger J, et al. Can. histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3–4 rectal cancer predict for 3-year disease-free survival. Int J Radiat Oncol Biol Phys. 2005;63:745–52.
    1. The Mercury Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333:779.
    1. Pilipshen SJ, Heilweil M, Quan SH, et al. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer. 1984;53:1354–62.
    1. Quirke P. Minimum dataset for Colorectal Cancer Histopathology Reports. Royal College of Pathologists; 1998.
    1. Rao S, Cunningham D, Price T, et al. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer. 2004;91:839–43.
    1. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96.
    1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.
    1. Shivnani T, Small W, Stryker SJ, et al. Preoperative chemoradiation in Rectal Cancer: Correlation Of tumor response with survival. J Clin Oncol proc, abstr. 2004;247
    1. Treurniet-Donker AD, Van Putten WL, Wereldsma JC, et al. Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in The Netherlands. Cancer. 1991;67:2042–8.
    1. Willett C, Tepper JE, Cohen A, et al. Local failure following curative resection of colonic adenocarcinoma. Int J Radiat Oncol Biol Phys. 1984;10:645–51.
    1. Willett CG, Fung CY, Kaufman DS, et al. Postoperative radiation therapy for high-risk colon carcinoma. J Clin Oncol. 1993;11:1112–7.

Source: PubMed

3
Subscribe